FRIDAY, June 28, 2019 — Total survival amongst older adults with diffuse massive B-cell lymphoma (DLBCL) has improved over time, however five-year survival is lower than 40 p.c, in line with a research revealed on-line June 12 in Leukemia & Lymphoma.
Jaime Shaw, from Amgen Inc. in Thousand Oaks, California, and colleagues describe temporal traits in therapy amongst sufferers ≥66 years outdated identified with DLBCL. A complete of 18,058 DLBCL sufferers from the Surveillance, Epidemiology, and Finish Outcomes-linked Medicare database have been included and had been identified between 2001 and 2013.
The researchers discovered that rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) was the most typical frontline remedy among the many 65 p.c of sufferers receiving therapy after analysis; R-CHOP use elevated from 51 p.c in 2001 to 2003 to 69 p.c in 2010 to 2014. In these Medicare sufferers, autologous and allogeneic hematopoietic stem cell transplantation was unusual. There was an improved survival price over time, concurrent with the rise in rituximab over time; effectiveness was not assessed on this research. In more moderen years, general survival estimates indicated regular enchancment in survival chances, though five-year survival was lower than 40 p.c.
“These information present perception into present therapy methods of DLBCL and adjustments which have occurred over time,” the authors write. “To enhance outcomes for older grownup DLBCL sufferers, simpler and tolerable therapeutic choices are wanted.”
The research was funded by Amgen.
Summary/Full Textual content
© 2019 HealthDay. All rights reserved.
Posted: June 2019